NCT06867107Phase 2Recruiting

An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101

Study sponsor: Satellos Bioscience, Inc. · MSLE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-09-30Estimated
Enrollment · participants30Estimated
Source updated2026-11-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Enrolling by invitation. After: Recruiting.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Treatment emergent adverse events Description: Incidence, temporal profile, and severity of treatment emergent adverse events (TEAEs) Time frame: 24 months Measure: SAT-3247 effect on fat fraction in biceps brachii Description: Changes from baseline in intramuscular fat fraction in muscle quantitative magnetic resonance (qMR) in biceps brachii following treatment with SAT-3247. Time frame: 24 months. After: Measure: Treatment emergent adverse events Description: Incidence, temporal profile, and severity of treatment emergent adverse events (TEAEs) Time frame: 12 months Measure: SAT-3247 effect on fat fraction in biceps brachii Description: Changes from baseline in intramuscular fat fraction in muscle quantitative magnetic resonance (qMR) in biceps brachii following treatment with SAT-3247. Time frame: 12 months.

Check registry source

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Treatment emergent adverse events. After: Measure: Treatment emergent adverse events Measure: SAT-3247 effect on fat fraction in biceps brachii.

Planned enrollment increased by 20 participants

Before: 10 participants (planned). After: 30 participants (planned).

Primary completion date changed

Before: 30 Aug 2026. After: 30 Sep 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview